Rapid degeneration of cultured human brain pericytes by amyloid betha protein by Verbeek, M.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/24754
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
Journal of Neurochemistry 
Lippincott-Raven Publishers, Philadelphia 
© 1997 International Society for Neurochemistry
Rapid Degeneration of Cultured Human Brain Pericytes 
by Amyloid ß Protein
Marcel M. Verbeek, Robert M. W. de Waal, * J anine J. Schipper, 
and *t William E. Van Nostrand
Department o f Pathology, University Hospital Nijmegen, Nijmegen, The Netherlands; * Department o f Microbiology
and Molecular Genetics, University o f California, Irvine, California; and t  Department o f Medicine,
Health Science Center, State University o f New York, Stony Brook, New York, U.S.A.
Abstract: Amyloid /3 protein (A/3) deposition in the cere­
bral arterial and capillary walls is one of the major charac­
teristics of brains from patients with Alzheimer’s disease 
and hereditary cerebral hemorrhage with amyloidosis- 
Dutch type (HCHWA-D). Vascular A/3 deposition is ac­
companied by degeneration of smooth muscle cells and 
pericytes. In this study we found that A/3^aq carrying the 
“Dutch” mutation (HCHWA-D A/?i_40) as well as wild- 
type A/ ^ -4 2  induced degeneration of cultured human 
brain pericytes and human leptomeningeal smooth mus­
cle cells, whereas wild-type A/3-,-4o and HCHWA-D 
A/31-42 were inactive. Cultured brain pericytes appeared 
to be much more vulnerable to A/3-induced degeneration 
than leptomeningeal smooth muscle cells, because in 
brain pericyte cultures cell viability already decreased 
after 2 days of exposure to HCHWA-D A/J^o, whereas 
in leptomeningeal smooth muscle cell cultures cell death 
was prominent only after 4-5 days. Moreover, leptomen­
ingeal smooth muscle cell cultures were better able to 
recover than brain pericyte cultures after short-term treat­
ment with HCHWA-D A A _40 ■ Degeneration of either cell 
type was preceded by an increased production of cellular 
amyloid precursor protein. Both cel! death and amyloid 
precursor protein production could be inhibited by the 
amyloid-binding dye Congo red, suggesting that fibril as­
sembly of A/? is crucial for initiating its destructive effects. 
These data imply an important role for A¡3 in inducing 
perivascular cell pathology as observed in the cerebral 
vasculature of patients with Alzheimer’s disease or 
HCHWA-D. Key Words: Alzheimer’s disease—Amyloid 
¡3 protein— Cerebrovasculature— Degeneration— Peri­
cytes—Smooth muscle cells.
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Senile plaques and cerebrovascular amyloid are two 
of the characteristic pathologic lesions in the brains of 
patients with Alzheimer’s disease (Mandybur, 1975; 
Glenner et al., 1981; Khachaturian, 1985). The major 
component of these lesions is the 39-42-amino-acid 
amyloid ft protein (A/3) (Glenner and Wong, 1984a), 
which is formed by proteolytic cleavage of the amyloid 
precursor protein (APP) (Kang et al., 1987; Ponte et
al., 1988). Similar deposits of A/3 are observed in 
brains of patients with D ow n’s syndrome and heredi­
tary cerebral hemorrhage with amyloidosis-Dutch type 
(HCHW A-D) (Glenner and Wong, 1984Z?; Luyendijk 
et aL, 1988 ). The latter disease is caused by a mutation 
at amino acid 22 of the A/3 sequence (Levy et al.,
1990), resulting in the formation of extensive cerebro­
vascular amyloid, often leading to fatal hemorrhages.
Cerebrovascular A/3 deposition is observed in lepto­
meningeal arteries as well as in cortical arterioles and 
capillaries. An important role in the production of 
cerebrovascular A/3 has been assigned to smooth mus­
cle cells (SM Cs) because APP and A/? have been 
immunohistochemically identified in or adjacent to 
these cells (Shoji et a l, 1990; Tagliavini et al., 1990; 
Yamaguchi et a l, 1992; Frackowiak et al., 1994; W is­
niewski and Wegiel, 1994), and cultured SMCs have 
been shown to produce and secrete APP (Van Nos­
trand et al., 1994). Besides, SMCs in amyloid-laden 
vessels are subject to degeneration, suggesting a toxic 
effect of amyloid or A/3 (Kawai et al., 1993; Wisniew­
ski and Wegiel, 1994).
In a previous report, the toxicity of A/?i_42, but not 
the shorter isoform A/91_40, for cultured leptomenin­
geal SMCs has been described (Davis-Salinas et al., 
1995). Furthermore, replacing glutamic acid at posi­
tion 22 of A/3 by glutamine, as in HCHWA-D (Levy 
et alM 1990), caused a remarkable reversal in the toxic
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effects of the A/3 peptides: HCHWA-D A /J^o , but not 
HCHWA-D A/3i_42, caused degeneration of cultured 
SMCs (Davis and Van Nostrand, 1996). A/?-induced 
degeneration of cultured SMCs was accompanied by 
an increase in APP and A/3 production (Davis-Salinas 
and Van Nostrand, 1995; Davis-Salinas et al., 1995), 
suggesting a self-amplifying process of A/3 and APP 
production and cellular degeneration.
Deposition of A/3 also occurs in capillaries of the 
cortex of brains from Alzheimer’s disease patients. 
Pericytes are a ubiquitous and prominent cell type of 
microvessels, located in a periendothelial position 
(Rhodin, 1980; Diaz-Flores et al.51991). Their pheno­
typic relation with SMCs and their position close to 
microvascular A(3 deposits suggest that pericytes may 
be involved in amyloid formation in cerebral capillar­
ies* Besides, pericytes in amyloid-containing capillar­
ies are prone to degeneration (Wisniewski et aL,
1992). Previously, we described the isolation and char­
acterization of human brain pericytes (HBPs) (Ver­
beek et al., 1994) and SMCs (Van Nostrand et al,,
1994) from human autopsy tissue. In this study we 
describe the effects of various synthetic A/3 peptides 
on the degeneration of these cell types and their APP 
metabolism. We show that HBPs are more vulnerable 
to, and have a lower capacity to recover from, A/3- 
induced degeneration than SMCs. Furthermore, in both 
cell types cellular degeneration is preceded by an in­
crease in APP production, and both these processes 
are probably mediated by assembly of A/?.
MATERIALS AND METHODS 
Materials
The A/3 peptides used in this study were synthesized and 
characterized as described previously (Davis-Salinas et al.,
1995). The following peptides were used: A^i_40» A/3i_42, 
HCHWA-D A/?!.«, and HCHWA-D A¡ 3 ^ .  The HCHWA- 
D peptides contain a glutamine at amino acid 22 instead of a 
glutamic acid. Lyophilized peptides were dissolved in sterile 
water at 250 fiM.
Cell culture
HBPs and human leptomeningeal SMCs (HLSMCs) were 
isolated and characterized as described previously (Van Nos­
trand et al., 1994; Verbeek et al., 1994, 1995). Cells were 
maintained in Eagle’s modification of essential medium sup­
plemented with 10% human serum (Gemini BioProducts, 
Calabasas, CA, U.S,A.), 10% newborn calf serum (Life 
Technologies), 150 ¿¿g/ml endothelial cell growth factor, 
and antibiotics. For degeneration experiments, triplicate 
wells with cultured cells were preincubated with Eagle’s 
modification of essential medium containing 0 .1% bovine 
serum albumin, 1 ¿¿g/ml hydrocortisone, 2 0  ng/ml insulin- 
like growth factor, and antibiotics (serum-free medium) for
4 h. Subsequently, cells were incubated with fresh serum- 
free medium, supplemented with synthetic A/3 peptides at 
25 jiM, for 6-12 days. Cells were routinely inspected and 
photographed using an Olympus phase-contrast microscope. 
Cell viability was quantified using a fluorescent live/dead 
cell assay according to the manufacturer’s description (Mo­
lecular Probes). The cultures were examined using an Olym­
pus fluorescence microscope, and the percentage of dead 
cells was determined from at least two counts per well.
Western blotting analysis
After incubation culture supernatant was collected and 
diluted 1:1 with nonreducing sample buffer. Cells were 
washed once with phosphate-buffered saline and then solubi­
lized in the wells with lysis buffer [50 mM  Tris-HCl, 150 
mM  NaCl (pH 7.5), 1% sodium dodecyl sulfate (SDS),
5 mM EDTA, 500 fiM 4-(2-aminoethyl)benzenesulfonyl 
fluoride, 10 /ig/ml leupeptin, and 10 /xg/ml chymostatm] 
for 15 min. After centrifugation at 14,000 g for 10 min, the 
protein content of diluted samples of the resulting superna­
tant was determined according to the method of Bradford 
(1976). Equal protein amounts were loaded and fractionated 
on nonreducing 10% SDS-polyacrylamide gels and subse­
quently electrophoretically transferred to Hybond nitrocellu­
lose membranes (Amersham Corp.) in blotting buffer [25 
mM Tris-HCl (pH 8 .6 ), 192 mM glycine, and 20% metha­
nol]. Blots were washed for 15 min in phosphate-buffered 
saline containing 0.05% Tween-20, preincubated with 
blocking solution (5% lowfat milk powder in PBST), 
washed three times with PBST, and subsequently incubated 
with anti-APP MAb P2-1 (Van Nostrand et al, 1989) and 
peroxidase-labeled sheep anti-mouse antibodies (Amer­
sham). Detection was performed by chemiluminescence ac­
cording to the manufacturer’s description (Amersham) and 
exposure to Kodak X-OMAT-R films. Signal intensities 
were quantified by scanning laser densitometry.
RESULTS
Synthetic A/3 peptides were applied to cultured 
HBPs and tested for their effects on morphology. 
Treatment of cultured HBPs with HCHWA-D A/3i_40 
(25 jJ,M) for 6  days clearly induced signs of cellular 
degeneration. Cell contours disappeared, indicating a 
disruption of the cell membrane, but all cells remained 
attached to the culture dish (Fig. 1). Similar, but less 
robust, effects on morphology were observed with 
wild-type A/3[-42 (25 /¿M, 6 days; data not shown). In 
contrast, incubation with either wild-type A/3 ,_4o or 
HCHWA-D A/?i_42 did not affect cell morphology 
(data not shown). Shortly after application, the 
HCHWA-D A/?i_42 peptide formed aggregates in solu­
tion, which was not observed with the other peptides. 
HCHWA-D A/31„40 was more potent in inducing cellu­
lar degeneration than wild-type A/3i_42; therefore, in 
the following experiments we concentrated on the ef­
fects of the HCHWA-D A/3^4 0  peptide only.
Addition of HCHWA-D Aj91_40 to HBP cultures 
strongly reduced the viability of the cells as determined 
by counting the numbers of live and dead cells in the 
cultures after 6  days, whereas, in accordance with the  
microscopic inspections, treatment with A/?i_40 o r 
HCHWA-D A/31 ^ 42 did not affect cell viability (Fig. 
2). The effects of synthetic A¡3 peptides on HLSM C 
cultures, treated in parallel experiments, were largely 
comparable to the effects on HBP cultures (data n o t 
shown). Visual inspection of the HLSMC and H B P  
cultures during a 6 -day treatment with w ild-type 
A/3, -42 or HCHWA-D A/?^4o revealed that degenera-
J. Neurochem., Vol. 68, No. 3, 1997
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FIG. 3. Induction of cellular and secreted APP in HBP cultures 
after A/3 treatment Top: Immunoblot analysis of cellular (lanes 
1 and 2) and secreted (lanes 3 and 4) APP in cultured HBPs 
incubated with control medium (Janes 1 and 3) or medium con­
taining HCHWA-D A/?t_40 (lanes 2 and 4). Sizes of molecular 
mass markers are indicated on the right in kDa. Bottom: Semi- 
quantitative densitometric analysis of the effects of various Ap 
peptides on the levels of cellular and secreted APP in cultured 
HBP. Data are mean ± SD (bars) values of representative experi­
ments. Statistical analysis was performed using Student’s t test. 
The level of significance of the difference from control values is 
indicated as follows: ***p < 0,001, *p < 0.05. p 0.05 is not 
indicated. D A A - 4o. HCHWA-D A /^ 40; D ApU42, HCHWA-D
A/3-1-42 .
number of viable cells in culture, APP expression fur­
ther increased between day 4 and 6  of the 6 -day 
HCHWA-D A/?j „4o treatment period.
In parallel experiments, HBPs and HLSMCs were 
treated with HCHWA-D A /J^ o  for 2 or 4  days and 
subsequently incubated in control medium for 4 or 2 
days, respectively, to test for their recovery capacity. 
During this second phase of incubation, cell viability 
of both HBP and HLSMC cultures further decreased 
(compare Fig. 6 A and 7A; e.g., 36% dead HBPs in 
Fig. 7A and 21% dead HBPs in Fig. 6 A after 2 days of 
HCHWA-D A/?i_40 treatment with or without recovery 
period, respectively), indicating that the adverse effect 
on viability could develop after removal of the toxic 
peptide. Short exposure (2 or 4 days) to HCHWA- 
D A/?i„4o followed by a period in control medium is
sufficient to induce maximal cell death over a 6 -day 
period in HBP cultures. Morphological examination of 
HLSMC cultures revealed that these cells were able 
to recover after such short-term ( 2 -4  days) exposure 
to HCHWA-D A/9^40; this was confirmed by determi­
nation of the number of dead cells that remained below 
maximal values (Fig. 7A). In HLSMC cultures, a 
strong increase in the number of dead cells required 
an exposure to the toxic peptide for 4 - 6  days.
Cell death in HBP cultures already reached plateau 
values when they were treated with HCHWA-D 
A/?i_4o for 2 or 4 days and counted at day 6 . However, 
when APP levels of either HBP or HLSMC cultures 
were compared in the case of treatment for 2 or 4 days 
with HCHWA-D A/?!_4o and direct analysis (Fig. 6 B) 
or harvested after a recovery period (Fig. 7B), the 
expression of APP was lower in the latter population» 
indicating a direct and reversible effect of A/3 on APP 
expression, in contrast to the effect on cell viability, 
which was more delayed.
DISCUSSION
In this report we described the effects of synthetic 
A(3 peptides on cultured HBPs as a model for A/3- 
induced cellular degeneration of the capillary wall. 
HCHWA-D A/3j_4o, but not the longer isoform 
HCHWA-D A/?,_42, induced degeneration of cultured 
HBPs, with a concomitant increase in cellular and se­
creted APP levels. Similar, but less robust, degenera­
tive effects were observed with wild-type A/?!_42 but 
not with A/3 ,_4o- These results are in agreement with 
several studies describing the effects of synthetic A/? 
peptides on cultured HLSMCs. Both HCHWA-D 
A(31 _4o and A/? 1-42, when added in a soluble form, 
similar to this study, caused degeneration of HLSMCs 
(Davis-Salinas et al., 1995; Davis and Van Nostrand, 
1996). In contrast, preaggregation of A(3 entirely abol-
& 20
control congo red D Aft^o D Ail mo
congo red
FIG. 4. Effects of exposure to HCHWA-D A/S^a (D A& -40) and 
Congo red on the viability of HBP cultures after 6 or 12 days of 
incubation. Congo red entirely inhibited the degenerative effects 
of D A/3i~4o* Data are mean ± SD (bars) values of three or more 
counts in a representative experiment. Statistical analysis was 
performed as described in the legend to Fig. 2.
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FIG. 5. Effects of HCHWA-D and Congo red on cellular 
APP levels in HBP cultures. Top: Immunoblot analysis of cellular 
APP levels in cultured HBP incubated with control medium (lane 
1), Congo red (25 [¿M; lane 2), HCHWA-D A/3-|_40 ( 25 pM; lane 
3), or HCHWA-D A/3-,_4o and Congo red simultaneously (lane 4). 
Sizes of molecular mass markers are indicated on the right in 
kDa. Bottom: Semiquantitative densitometric analysis of the ef­
fects of incubation with HCHWA-D A/?-,_40 (D A/31-40) and Congo 
red on the levels of cellular APP in cultured HBPs. Data are mean 
± SD (bars) values of representative experiments. Statistical 
analysis was performed as described in the legend to Fig. 2.
boring parenchyma (Scholz, 1938; Morel and Wildi, 
1952), As cultured HBPs are more sensitive to A¡3 
treatment and as capillaries only contain one layer of 
pericytes, in contrast to arteries, which contain multiple 
layers of SMCs, A/3-induced degeneration of pericytes 
may cause capillaries to disintegrate more easily than 
arteries, after which the amyloid may start to penetrate 
into the brain parenchyma, resulting in dyshoric angio­
pathy.
Our data also provided more insight into the dynam­
ics of A/3-induced cellular degeneration and the induc­
tion of APP production. The increase in cellular APP 
production is directly related to the presence of active 
A(3 isoforms, such as HCHWA-D A/?!_40, because 
short-term incubation induced an immediate increase 
in APP production and, after removal of the peptides, 
APP production decreased again. An increase in APP 
production may also involve increased production of 
endogenous A¡3 (Davis-Salinas et al., 1995) and of 
C-terminal fragments of APP (authors’ unpublished
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ished the effect on cultured HLSMCs (Davis-Salinas 
and Van Nostrand, 1995), whereas preaggregated A(3 
was more toxic to neuronal cell cultures than nonaggre­
gated A¡3 (Yankner et al., 1990; Pike et al., 1991,
1993). These data indicate that related cell types, such 
as HBPs and HLSMCs, respond similarly to A(3 treat­
ment but differ from neuronal cells in ¿heir response
to A/3.
However, quantitative differences could be observed 
in the effects of A ft on cultured HBPs or HLSMCs. 
In cultured HBPs, in contrast to cultured HLSMCs, 
treatment with HCHWA-D A /3i-4Q resulted in in­
creased levels of secreted soluble APP, which may 
relate to subtle differences in response of the different 
cell types. Furthermore, cultured HBPs were more vul­
nerable to HCHWA-D A / ? i_ 4o treatment than cultured 
HLSMCs. This observation may provide an explana­
tion for the phenomenon of dyshoric angiopathy in 
Alzheimer's disease brains, defined as fine radiating 
deposits of amyloid extending from amyloid-laden cor­
tical capillaries and small arterioles into the neigh-
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FIG. 6, Effect of short-term incubation with HCHWA-D A^1_40 
(0, 2, 4, or 6 days) on (A) viability and (B) cellular APP levels of 
HBP and SMC cultures. Data are mean ± SD (bars) values of 
a representative experiment. Statistical analysis was performed 
using Student's t test. The level of significance of the difference 
from control values is indicated as follows: ***p < 0.001, **p 
< 0.01, *p < 0.05. p ^ 0.05 is not indicated. The absolute levels 
of APP expression (as shown in B) may vary between the experi­
ments and between individual HBP and HLSMC cultures.
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FIG. 7. Effect of short-term incubation with HCHWA-D A/?i_40 
(0, 2, 4, or 6 days), followed by a recovery period in control 
medium for 6, 4, 2, or 0 days, respectively, on the (A) viability 
and (B) cellular APP levels of HBP and SMC cultures. Data 
are mean ± SD (bars) values of a representative experiment, 
Statistical analysis was performed as described in the legend to 
Fig. 6. C, incubation with control medium for the indicated num­
ber of days; D, similar incubation with medium containing 
HCHWA-D A ft .« .
data), which may thus contribute to the process of 
degeneration via an amplification loop. In contrast, 
however, induction of cell death seemed to have differ­
ent dynamics. After a short-term treatment with 
HCHWA-D A/?i_4o and subsequent removal of the 
peptide, cell viability continued to decrease for several 
days, indicating that the intracellular processes leading 
to cell death could not be reversed anymore.
The mechanisms leading to A/3-induced cell death 
are not clarified yet, but the experiments with Congo 
red point to a mechanism in which A¡3 assembly may 
be the crucial factor similar to what has been described 
for the neurotoxic effects of A/3 (Lorenzo and Yank- 
ner, 1994). Congo red inhibits neurotoxicity of AJ3 
either by binding to preformed fibrils or, alternatively, 
by inhibiting fibril formation (Lorenzo and Yankner,
1994). We also found that Congo red protected cul­
tured HBPs against cellular degeneration by HCHWA- 
D A/3^40, suggesting that A/3 assembly is a common 
mechanism in the destructive effects of A¡3 on various 
cell types. If assembly of A/3 is necessary for its toxic­
ity, the aggregation rate of each A/3 isoform may be 
decisive for its effect. Wild-type A/3i-42 fibrillizes 
faster than A/3j_4o (Jarrett et al., 1993), and in accor­
dance with this, wild-type A/?j _42 is toxic for cultured 
HBPs and SMCs, whereas A/3U4o is not. Furthermore, 
A/9 peptides containing the Dutch mutation have been 
described to assemble into fibrils more rapidly than 
wild-type A/3 (Wisniewski et al., 1991; Clements et 
alM 1993). In line with these observations, HCHWA- 
D A f3{_40 causes degeneration of cultured HBPs and 
SMCs, whereas wild-type A/3i_40 is nonactive. In anal­
ogy, it would be anticipated that HCHWA-D A/?i_42 
is even more toxic than HCHWA-D A/3i_40. However, 
HCHWA-D A/?i_42 is not cytotoxic for HBP or 
HLSMC cultures, which may be related to the observa­
tion that this peptide is the only one that very rapidly 
formed aggregates in solution, as was recently reported 
(Davis and Van Nostrand, 1996). Similar to the previ­
ous description of the absence of cellular degeneration 
after addition of preaggregated A/3i_42 to cultured 
HLSMCs (Davis-Salinas and Van Nostrand, 1995), 
these aggregates of HCHWA-D A(3{, a1 are not toxic 
for cultured HBPs. Although the protective effect o f 
Congo red suggests that assembly of A¡3 is essential 
for its cytotoxic effect on cultured HBPs, interaction 
with the cell surface during assembly seems to be cru­
cial too, as A/3 assembly in solution alone does not 
induce cellular degeneration.
In conclusion, A/3-induced cellular degeneration 
seems to be a cell-specific event, that, even in closely 
related cell types such as HBPs and HLSMCs, m ay 
result in different responses. Future study of the mech­
anisms of A/3-induced degeneration of cultured HBPs 
and HLSMCs may provide more insight into the mech­
anisms of cellular degeneration that is observed in A lz­
heimer’s disease and HCHWA-D brains. A common 
mechanism in A/3~induced cytotoxicity may be the for­
mation of A/3 fibrils during interaction of A/3 with 
target cells, although this needs further investigation. 
The data in this study support the important role for 
Af3 in causing vascular pathology as observed in Alz­
heimer’s disease and HCHWA-D brains and indicate 
that cultured human cerebrovascular cells may serve 
as a model for the study of vascular amyloid formation, 
which will allow for future preclinical testing of anti- 
amyloidogenic drugs.
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